Adaptimmune Therapeutics plc

Gilead Sciences’ Kite division is stepping into cell therapy for solid tumors with encouraging early efficacy data in one of the toughest of all cancers to treat, having presented Phase I results for

The end of the first quarter of 2025 and the beginning of Q2 have been rough for public biopharma companies, with the closely watched XBI fund falling first in reaction to layoffs at the US Food and D

The US Food and Drug Administration takes a “more pragmatic” approach to cell and gene therapy development, which provides companies with a “less stringent pathway” to show that their product has pote

“We’re at an exciting juncture in medicine where the perceived scientific boundaries in treatment across therapeutic areas continue to dissolve.” These words from Jeffrey Jones , chief medical office